Haemostatic Disorders

Haemostatic Disorders Content

COVID-19, Anaemia, Leukaemia, Myeloproliferative Disorders, Haematological Malignancies, Myelodysplastic Syndrome, Paediatric Haematology, Rare Diseases, Thrombocytopenia, White Blood Cell Disorders, Genetic Blood Disorders, Amyloidosis, Autoimmune Blood Disorders, Blood and Bone Marrow Transplantation, Bloodstream Infections, Haemostatic Disorders, Lymphoma, Maternal-foetal Medicine, Myeloma, Platelet Disorders, Policy, Transfusion Medicine

What’s on the horizon for continuing medical education? Insights from touchIME

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

Leukaemia, Haematological Malignancies, Haemostatic Disorders, Lymphoma

Dr Esra Gülderen on learning, leadership and lifelong growth: touchHAEMATOLOGY Future Leader 2025

Dr. Esra Gülderen discusses her path into hematology, the critical role of mentorship, and how early research experiences shaped her confidence. Now a Co-chair of the EBMT Trainee Committee, she shares what motivates her and why clear communication, curiosity, and resilience are essential traits for aspiring haematologists.

Supporting haematology patient care: Insights from the Haematology Nurses and Healthcare Professionals Group

Nurses account for the largest group of professionals in the healthcare system and there are an estimated 29 million nurses worldwide (WHO, 2024). Nursing practice needs to be dynamic in order to respond to the changing needs of an aging population and the increasing incidence of chronic diseases (WHO, 2022; Hacker, 2024). Within the haematology […]

Haemostatic Disorders

ISTH unveils new guidelines for haemophilia treatment

The International Society on Thrombosis and Haemostasis (ISTH) has issued an evidence-based clinical practice guideline aimed at revolutionizing the treatment landscape for congenital haemophilia A and B. Hemophilia, a rare bleeding disorder caused by deficiencies in blood coagulation factors, affects individuals worldwide and demands intricate management strategies.

Haemostatic Disorders

Phase 3 BASIS trial – efficacy and safety of marstacimab in severe haemophilia A or B without inhibitors: Davide Matino, ASH 2023

Watch Time: 8 mins

The Phase 3 BASIS trial assessed the efficacy and safety of marstacimab, a monoclonal antibody targeting the tissue factor pathway inhibitor, in participants with severe haemophilia A or moderately severe to severe haemophilia B without inhibitors. The study demonstrated marstacimab’s effectiveness in reducing bleeding events compared to previous therapies, along with its safety profile over […]

Feedback

Feedback

FILTER YOUR SEARCH

Content Type:

Speciality:

Conference:

Haemostatic Disorders